drugset
drugset / Trial / NCT06858397

A proof-of Concept Study to Assess Safety and Tolerability of HM15421/GC1134A in Patients With Fabry Disease

NCT06858397 ↗

Phase 1/2 Recruiting 18 enrolled GC Biopharma Corp Hanmi Pharmaceutical Company Limited · collab
Non-randomizedSequentialOpen-labelTreatment

Summary

This Phase 1/2 first-in-human (FIH) study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of HM15421 in patients with FD.

Timeline

Start
2025-05-14
Primary completion
2028-08-30
Completion
2028-08-30

Drugs

EvaluationDrugModalityDoseRoute
Subject HM15421 Unknown — —

Indications

Fabry disease